Trending: Moderna Shares Rise on Favorable Skin Cancer Study Results
2023年12月15日 - 5:26AM
Dow Jones News
14:55 ET -- Moderna is one of the most mentioned companies in
the U.S. across all news items in the last 12 hours, according to
Factiva data. Shares were up 8% to $84.96 after Moderna and partner
Merck disclosed positive trial results for an experimental
mRNA-based treatment for skin cancer. On Wednesday, shares of
Moderna and other makers of Covid-19 vaccines declined after Pfizer
warned about slower demand for its Covid-19 products. Dow Jones
& Co. owns Factiva. (josh.beckerman@wsj.com)
(END) Dow Jones Newswires
December 14, 2023 15:11 ET (20:11 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
過去 株価チャート
から 4 2024 まで 5 2024
Moderna (NASDAQ:MRNA)
過去 株価チャート
から 5 2023 まで 5 2024